Tuesday, May 22, 2018
Motus GI Holdings, Inc., a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that the Chinese Patent Office (SIPO) has granted a patent that covers the Company’s flagship product, the Pure-Vu® System. The Pure-Vu® System is a medical device that cleanses the colon during a colonoscopy procedure to facilitate improved visualization enabling a quality exam.
“With colorectal cancer being one of the top three most commonly diagnosed cancers in the world, accounting for over 1.4 million new cases and 700,000 deaths, it is important that we bring the Pure-Vu® System to patients across the globe over the next several years,” said Mark Pomeranz, CEO of Motus GI. “We are dedicated to building a solid IP portfolio, in both the U.S. and internationally, to support our strategic positioning and protection of the Pure-Vu® System in key global markets. We believe that building our IP infrastructure now is critical to support our commercial launch and achieve our goal to establish the Pure-Vu® System as a new standard of care for inpatient colonoscopy procedures worldwide.”
The Pure-Vu® System is currently being introduced on a pilot basis in the U.S. market. The Company is planning to initiate a broader commercial launch in the U.S. and select international markets in 2019 with a focus on the inpatient, hospital-based colonoscopy market where challenges with insufficient bowel prep slow diagnosis, diminish the quality of care and add significant costs for hospitals. The Company believes the Pure-Vu® System may potentially reduce healthcare costs by reliably and predictably moving patients through the system to a successful examination.
“Reports from the World Health Organization indicated that colorectal cancer rates were rapidly rising in many Asian countries including China, Japan, Korea and Singapore, so as we look into the future we are excited about the potential in these growing markets,” concluded Mr. Pomeranz.
